Placebo + AGN-151586
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Glabellar Lines
Conditions
Glabellar Lines
Trial Timeline
Mar 16, 2022 → Mar 17, 2023
NCT ID
NCT05248867About Placebo + AGN-151586
Placebo + AGN-151586 is a phase 3 stage product being developed by AbbVie for Glabellar Lines. The current trial status is completed. This product is registered under clinical trial identifier NCT05248867. Target conditions include Glabellar Lines.
What happened to similar drugs?
0 of 10 similar drugs in Glabellar Lines were approved
Approved (0) Terminated (0) Active (10)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05248867 | Phase 3 | Completed |
Competing Products
19 competing products in Glabellar Lines
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AGN-151586 + BOTOX + Placebo | AbbVie | Phase 1 | 29 |
| AGN-151586 + Placebo | AbbVie | Phase 3 | 40 |
| AGN-151586 + OnabotulinumtoxinA + Placebo | AbbVie | Phase 1 | 29 |
| AGN-151586 + Placebo | AbbVie | Phase 3 | 40 |
| AGN-151586 | AbbVie | Phase 3 | 40 |
| AGN-151586 + Placebo | AbbVie | Phase 1 | 29 |
| Botulinum toxin type A + Botulinum toxin type A + Placebo + Placebo | Ipsen | Phase 3 | 37 |
| IPN10200 + Placebo | Ipsen | Phase 3 | 44 |
| Botulinum toxin type A + Placebo | Ipsen | Phase 3 | 37 |
| Botulinum toxin type A + Botulinum toxin type A + Placebo | Ipsen | Phase 2 | 32 |
| Botulinum toxin type A + Placebo | Ipsen | Phase 3 | 37 |
| IPN10200 + Placebo | Ipsen | Phase 3 | 44 |
| prabotulinumtoxinA | Evolus | Pre-clinical | 20 |
| PrabotulinumtoxinA-Xvfs + OnabotulinumtoxinA + PrabotulinumtoxinA-Xvfs | Evolus | Phase 2 | 25 |
| Botulinum toxin, Type A | Evolus | Phase 3 | 30 |
| DWP-450 (Botulinum purified neurotoxin, Type A) | Evolus | Phase 2 | 25 |
| Botulinum toxin, Type A | Evolus | Phase 3 | 30 |
| Botulinum purified neurotoxin, Type A | Evolus | Phase 2 | 25 |
| prabotulinumtoxinA | Evolus | Phase 1 | 19 |